FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034196776> ?p ?o ?g. }

• W2034196776 endingPage "39" @default.
• W2034196776 startingPage "33" @default.
• W2034196776 abstract "BackgroundIgE sensitization to Aspergillus fumigatus and a positive sputum fungal culture result are common in patients with refractory asthma. It is not clear whether these patients would benefit from antifungal treatment.ObjectivesWe sought to determine whether a 3-month course of voriconazole improved asthma-related outcomes in patients with asthma who are IgE sensitized to A fumigatus.MethodsAsthmatic patients who were IgE sensitized to A fumigatus with a history of at least 2 severe exacerbations in the previous 12 months were treated for 3 months with 200 mg of voriconazole twice daily, followed by observation for 9 months, in a double-blind, placebo-controlled, randomized design. Primary outcomes were improvement in quality of life at the end of the treatment period and a reduction in the number of severe exacerbations over the 12 months of the study.ResultsSixty-five patients were randomized. Fifty-nine patients started treatment (32 receiving voriconazole and 27 receiving placebo) and were included in an intention-to-treat analysis. Fifty-six patients took the full 3 months of medication. Between the voriconazole and placebo groups, there were no significant differences in the number of severe exacerbations (1.16 vs 1.41 per patient per year, respectively; mean difference, 0.25; 95% CI, 0.19-0.31), quality of life (change in Asthma Quality of Life Questionnaire score, 0.68 vs 0.88; mean difference between groups, 0.2; 95% CI, −0.05 to −0.11), or any of our secondary outcome measures.ConclusionWe were unable to show a beneficial effect of 3 months of treatment with voriconazole in patients with moderate-to-severe asthma who were IgE sensitized to A fumigatus on either the rate of severe exacerbations, quality of life, or other markers of asthma control. IgE sensitization to Aspergillus fumigatus and a positive sputum fungal culture result are common in patients with refractory asthma. It is not clear whether these patients would benefit from antifungal treatment. We sought to determine whether a 3-month course of voriconazole improved asthma-related outcomes in patients with asthma who are IgE sensitized to A fumigatus. Asthmatic patients who were IgE sensitized to A fumigatus with a history of at least 2 severe exacerbations in the previous 12 months were treated for 3 months with 200 mg of voriconazole twice daily, followed by observation for 9 months, in a double-blind, placebo-controlled, randomized design. Primary outcomes were improvement in quality of life at the end of the treatment period and a reduction in the number of severe exacerbations over the 12 months of the study. Sixty-five patients were randomized. Fifty-nine patients started treatment (32 receiving voriconazole and 27 receiving placebo) and were included in an intention-to-treat analysis. Fifty-six patients took the full 3 months of medication. Between the voriconazole and placebo groups, there were no significant differences in the number of severe exacerbations (1.16 vs 1.41 per patient per year, respectively; mean difference, 0.25; 95% CI, 0.19-0.31), quality of life (change in Asthma Quality of Life Questionnaire score, 0.68 vs 0.88; mean difference between groups, 0.2; 95% CI, −0.05 to −0.11), or any of our secondary outcome measures. We were unable to show a beneficial effect of 3 months of treatment with voriconazole in patients with moderate-to-severe asthma who were IgE sensitized to A fumigatus on either the rate of severe exacerbations, quality of life, or other markers of asthma control." @default.
• W2034196776 created "2016-06-24" @default.
• W2034196776 creator A5010778546 @default.
• W2034196776 creator A5011255987 @default.
• W2034196776 creator A5011783780 @default.
• W2034196776 creator A5012724344 @default.
• W2034196776 creator A5025055562 @default.
• W2034196776 creator A5043495928 @default.
• W2034196776 creator A5046848632 @default.
• W2034196776 creator A5048320859 @default.
• W2034196776 creator A5060939405 @default.
• W2034196776 creator A5068562227 @default.
• W2034196776 creator A5069887200 @default.
• W2034196776 creator A5080083216 @default.
• W2034196776 creator A5081966960 @default.
• W2034196776 creator A5088376563 @default.
• W2034196776 date "2014-07-01" @default.
• W2034196776 modified "2023-10-06" @default.
• W2034196776 title "Effectiveness of voriconazole in the treatment of Aspergillus fumigatus–associated asthma (EVITA3 study)" @default.
• W2034196776 cites W1561293316 @default.
• W2034196776 cites W1857079041 @default.
• W2034196776 cites W1974893215 @default.
• W2034196776 cites W1987920075 @default.
• W2034196776 cites W1988758075 @default.
• W2034196776 cites W2010825301 @default.
• W2034196776 cites W2017674647 @default.
• W2034196776 cites W2033391872 @default.
• W2034196776 cites W2034519404 @default.
• W2034196776 cites W2075231539 @default.
• W2034196776 cites W2088225529 @default.
• W2034196776 cites W2088624642 @default.
• W2034196776 cites W2092701584 @default.
• W2034196776 cites W2104608591 @default.
• W2034196776 cites W2124265863 @default.
• W2034196776 cites W2126870687 @default.
• W2034196776 cites W2135649656 @default.
• W2034196776 cites W2144398374 @default.
• W2034196776 cites W2147711737 @default.
• W2034196776 cites W2152001616 @default.
• W2034196776 cites W2154263136 @default.
• W2034196776 cites W4211151481 @default.
• W2034196776 cites W4245291408 @default.
• W2034196776 cites W4297852198 @default.
• W2034196776 doi "https://doi.org/10.1016/j.jaci.2013.09.050" @default.
• W2034196776 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24290286" @default.
• W2034196776 hasPublicationYear "2014" @default.
• W2034196776 type Work @default.
• W2034196776 sameAs 2034196776 @default.
• W2034196776 citedByCount "71" @default.
• W2034196776 countsByYear W20341967762014 @default.
• W2034196776 countsByYear W20341967762015 @default.
• W2034196776 countsByYear W20341967762016 @default.
• W2034196776 countsByYear W20341967762017 @default.
• W2034196776 countsByYear W20341967762018 @default.
• W2034196776 countsByYear W20341967762019 @default.
• W2034196776 countsByYear W20341967762020 @default.
• W2034196776 countsByYear W20341967762021 @default.
• W2034196776 countsByYear W20341967762022 @default.
• W2034196776 countsByYear W20341967762023 @default.
• W2034196776 crossrefType "journal-article" @default.
• W2034196776 hasAuthorship W2034196776A5010778546 @default.
• W2034196776 hasAuthorship W2034196776A5011255987 @default.
• W2034196776 hasAuthorship W2034196776A5011783780 @default.
• W2034196776 hasAuthorship W2034196776A5012724344 @default.
• W2034196776 hasAuthorship W2034196776A5025055562 @default.
• W2034196776 hasAuthorship W2034196776A5043495928 @default.
• W2034196776 hasAuthorship W2034196776A5046848632 @default.
• W2034196776 hasAuthorship W2034196776A5048320859 @default.
• W2034196776 hasAuthorship W2034196776A5060939405 @default.
• W2034196776 hasAuthorship W2034196776A5068562227 @default.
• W2034196776 hasAuthorship W2034196776A5069887200 @default.
• W2034196776 hasAuthorship W2034196776A5080083216 @default.
• W2034196776 hasAuthorship W2034196776A5081966960 @default.
• W2034196776 hasAuthorship W2034196776A5088376563 @default.
• W2034196776 hasBestOaLocation W20341967762 @default.
• W2034196776 hasConcept C126322002 @default.
• W2034196776 hasConcept C141105273 @default.
• W2034196776 hasConcept C142724271 @default.
• W2034196776 hasConcept C159110408 @default.
• W2034196776 hasConcept C159654299 @default.
• W2034196776 hasConcept C16005928 @default.
• W2034196776 hasConcept C168563851 @default.
• W2034196776 hasConcept C203014093 @default.
• W2034196776 hasConcept C204787440 @default.
• W2034196776 hasConcept C207480886 @default.
• W2034196776 hasConcept C27081682 @default.
• W2034196776 hasConcept C2776042228 @default.
• W2034196776 hasConcept C2776301714 @default.
• W2034196776 hasConcept C2776391196 @default.
• W2034196776 hasConcept C2778871687 @default.
• W2034196776 hasConcept C2779548794 @default.
• W2034196776 hasConcept C2779787849 @default.
• W2034196776 hasConcept C2779951463 @default.
• W2034196776 hasConcept C2780690907 @default.
• W2034196776 hasConcept C2781069245 @default.
• W2034196776 hasConcept C71924100 @default.
• W2034196776 hasConceptScore W2034196776C126322002 @default.
• W2034196776 hasConceptScore W2034196776C141105273 @default.

• next